Clinical analysis of the mechanism of action and therapeutic effect of mobosetinib (Anweili)

Mobocertinib (Mobocertinib) is a new oral tyrosine kinase inhibitor (TKI), mainly targeting EGFR present in non-small cell lung cancer (NSCLC) Exon20Insertion mutation (EGFR exon20 insertion) patients. Traditional EGFR-TKI is less sensitive to this type of mutation, while mobosetinib inhibits the excessive activation of signaling pathways by specifically binding to the active site of mutant EGFR , thereby preventing the growth and spread of cancer cells. This mechanism fills the gap in the previous treatment of patients with EGFR exon20 mutations and provides a new solution for precision medicine.

In terms of clinical therapeutic effects, mobosetinib has shown positive efficacy in multiple II phase clinical trials. Research data shows that the objective response rate (ORR) of patients with EGFR exon20 insertion mutation NSCLC who received mobosetinib reached approximately 28%–35%, and the disease control rate (DCR) can exceed 75%. In addition, the median progression-free survival (PFS) of some patients is around 7–9 months, which is significantly improved compared with traditional chemotherapy regimens. Although the overall response rate is not as good as that of common EGFR mutation-targeted drugs, mobosetinib is still of great significance in a patient group that lacks effective treatments.

It is worth noting that the side effects of mobosetinib mainly include diarrhea, rash, loss of appetite, nausea, and electrolyte imbalance. Diarrhea is the most common side effect and usually needs to be controlled with antidiarrheal medications or dose adjustments. Some patients may also experience heart-related adverse reactions such as QT prolongation of the interval, so regular electrocardiogram monitoring and electrolyte level checks are required during treatment. Clinicians often flexibly adjust dosages based on patient tolerance to improve drug acceptability and compliance.

Overall, the launch of moboxetinib is EGFR exon20 Insertion mutations NSCLC Patients bring new targeted treatment options. It not only improves the limited treatment status of this population, but also provides valuable experience for the future development of precision medicine. As more long-term follow-up data and real-world study results accumulate, the potential of mobosertinib in terms of survival benefit, improvement in quality of life, and combination with other treatments is expected to be further confirmed.

Reference link:https://www.drugs.com